Product Overview
SL-327 is a selective inhibitor of MEK1 and MEK2 with IC50 values of 0.18 and 0.22μM, respectively. MEK1 and MEK2 (ERK) are a kinase enzyme which phosphorylate mitogen-activated protein kinase (MAPK). Extracellular signal-regulated kinase (ERK) activity is essential for the acquisition of associative learning tasks. In adult male CD-1 mice, SL-327 inhibited Pp-ERK immunostaining in the nuclei of the cells induced by cocaine. SL-327 pretreatment inhibited c-Fos expression in nuclear and inhibited activation of ERK within all the amygdala, namely LA, BLA, BMP, Ce and MePD. In morphine-pretreated rats, SL-327 increased (58%) the expression of morphine-induced psychomotor sensitization (SW3) and fully prevented the upregulation of p-PEA-15, p-FADD, and p-Akt1 at SW3. In adult male DBA/2J mice, SL-327 significantly reduced pERK levels by 40% in both the motor cortex and dorsal striatum. In rat model, SL-327 inhibited MAPK/ERK cascade, which prevented LTP-dependent gene induction and CREB and Elk-1 phosphorylation, resulting in rapidly decaying LTP.